






Program	Target	Disease	Lead Optimize	Preclinical	Phase I
KAR2261 Cancer	HDAC	Cancer			
KAR2581 Inflammation	HDAC	RA Psoriasis Transplantation			
KAR3000 Inflammation	HDAC-6	Immune- inflammation			
KAR4000 Inflammation	PI3K p110 $\beta$ / $\delta$ dual selective	Immune- inflammation			
KAR4000 Cancer	PI3K p110 $\beta$	PTEN null solid tumors			
	PI3K p110 $\delta$	Hematological cancers	